Investor Relations
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>
Jun 11, 2018
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity MORE >>
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>

SEC Filings

Form Description Filing date View
D View HTML
D View HTML
15-12G

15-12G    

View HTML
424B7

424B7    

View HTML
424B7

424B7    

View HTML
PRE 14C

A preliminary proxy statement containing all other information

View HTML
PRE 14C

A preliminary proxy statement containing all other information

View HTML
PRE 14C

A preliminary proxy statement containing all other information

View HTML
PRE 14C

A preliminary proxy statement containing all other information

View HTML
PRE 14A

A preliminary proxy statement providing notification matters to be brought to a vote

View HTML